DelveInsight’s “Minimal Residual Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Minimal Residual Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Minimal Residual Disease Market Forecast
Some of the key facts of the Minimal Residual Disease Market Report:
- The Minimal Residual Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In the United States, there are around 6,000 individuals with ALL, with half of them being children and the other half adults, according to the study by Jabbour and Park (2022)
- The overall number of minimal residual disease testing cases in the 7MM for the year 2021 was determined to be 1,219,739 cases. The US and Germany were the two countries with the highest number of MRD testing cases
- A significant number of adult ALL patients experience relapse despite reaching complete remission (CR), with a reported relapse incidence of 40–50%, according to CatALLyst (2021). Additionally, 30–40% of patients who achieve CR test positive for MRD, suggesting that they may still have some cancer cells in their bone marrow
- In the 7MM, there were 98,720, 368,298, 339,478, 149,497, 15,992, and 247,754 MRD tests performed on blood malignancies in the year 2021, for ALL, CLL, AML, CML, MM, and Lymphoma, respectively
- Key Minimal Residual Disease Companies: Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
- Key Minimal Residual Disease Therapies: ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others
- The Minimal Residual Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Minimal Residual Disease pipeline products will significantly revolutionize the Minimal Residual Disease market dynamics.
Minimal Residual Disease Overview
Small quantities of cancer cells that remain in the body after treatment are known as minimal residual disease (MRD). These cells have the capacity to recur and trigger relapses. For instance, in leukaemia, doctors examine bone marrow samples under a microscope for cancer cells to see if the disease has responded to treatments.
Get a Free sample for the Minimal Residual Disease Market Report
https://www.delveinsight.com/report-store/minimal-residual-disease-market
Minimal Residual Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Minimal Residual Disease Epidemiology Segmentation:
The Minimal Residual Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Minimal Residual Disease
- Prevalent Cases of Minimal Residual Disease by severity
- Gender-specific Prevalence of Minimal Residual Disease
- Diagnosed Cases of Episodic and Chronic Minimal Residual Disease
Download the report to understand which factors are driving Minimal Residual Disease epidemiology trends @ Minimal Residual Disease Epidemiology Forecast
Minimal Residual Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Minimal Residual Disease market or expected to get launched during the study period. The analysis covers Minimal Residual Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Minimal Residual Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Minimal Residual Disease Therapies and Key Companies
- ClonoSEQ: Adaptive Biotechnologies
- PhasED-Seq: Foresight Diagnostics
- Targeted Locus Amplification (TLA) technology: Cergentis B.V.
- MRDx BCR-ABL Test: ICON plc
- TRUPCR® PML-RARA: 3B BlacBio Biotech
- Signatera: Natera
- Leukemia Fusion Gene One-Step Detection Kits: EntroGen
- CBFB/MYH11 inv(16): Quest Diagnostics
- Seq-MRD: ImmuQuad
- PhasED-Seq: Foresight Diagnostics
- Targeted Locus Amplification (TLA) technology: Cergentis B.V.
- TRUPCR® PML-RARA: 3B BlacBio Biotech
- CBFB/MYH11 inv(16): Quest Diagnostics
- LymphoTrack: Invivoscribe Inc.Biocartis: Idylla Technology
Discover more about therapies set to grab major Minimal Residual Disease market share @ Minimal Residual Disease Treatment Market
Minimal Residual Disease Market Strengths
- Several organizations and companies like the European Scientific foundation for Laboratory Hemato Oncology (ESLHO), Leukemia and Lymphoma Society (LLS) and European LeukemiaNet (ELN), among many more, are raising awareness about the disease, which can lead to the increased patient pool.
- The recent advances in high-throughput technologies in molecular genetics may now provide a novel approach to detect MRD like next-generation sequencing (NGS).
Minimal Residual Disease Market Opportunities
- Increased use of MRD testing can create new opportunities by identifying the patients who could benefit from consolidative HDT-ASCT and/or prolonged therapy.
- The development of more accurate diagnostic methods with high sensitivity can detect even the smallest amount of MRD cells.
Scope of the Minimal Residual Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Minimal Residual Disease Companies: Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
- Key Minimal Residual Disease Therapies: ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others
- Minimal Residual Disease Therapeutic Assessment: Minimal Residual Disease current marketed and Minimal Residual Disease emerging therapies
- Minimal Residual Disease Market Dynamics: Minimal Residual Disease market drivers and Minimal Residual Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Minimal Residual Disease Unmet Needs, KOL’s views, Analyst’s views, Minimal Residual Disease Market Access and Reimbursement
To know more about Minimal Residual Disease companies working in the treatment market, visit @ Minimal Residual Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Minimal Residual Disease Market Report Introduction
2. Executive Summary for Minimal Residual Disease
3. SWOT analysis of Minimal Residual Disease
4. Minimal Residual Disease Patient Share (%) Overview at a Glance
5. Minimal Residual Disease Market Overview at a Glance
6. Minimal Residual Disease Disease Background and Overview
7. Minimal Residual Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Minimal Residual Disease
9. Minimal Residual Disease Current Treatment and Medical Practices
10. Minimal Residual Disease Unmet Needs
11. Minimal Residual Disease Emerging Therapies
12. Minimal Residual Disease Market Outlook
13. Country-Wise Minimal Residual Disease Market Analysis (2019–2032)
14. Minimal Residual Disease Market Access and Reimbursement of Therapies
15. Minimal Residual Disease Market Drivers
16. Minimal Residual Disease Market Barriers
17. Minimal Residual Disease Appendix
18. Minimal Residual Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/